Adriana M Hung1,2, Yohei Tsuchida3, Kristen L Nowak4, Sudipa Sarkar2, Michel Chonchol4, Victoria Whitfield2, Natjalie Salas2, Anna Dikalova2, Patricia G Yancey2, Jiansheng Huang2, MacRae F Linton2, T Alp Ikizler5,2, Valentina Kon6. 1. Division of Nephrology, Tennessee Valley Healthcare System, Nashville, Tennessee; Valentina.Kon@vanderbilt.edu Adriana.Hung@vanderbilt.edu. 2. Department of Medicine and. 3. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee; and. 4. Department of Medicine, University of Colorado Denver, Aurora, Colorado. 5. Division of Nephrology, Tennessee Valley Healthcare System, Nashville, Tennessee. 6. Department of Pediatrics, Vanderbilt University Medical Center, Nashville, Tennessee; and Valentina.Kon@vanderbilt.edu Adriana.Hung@vanderbilt.edu.
Abstract
BACKGROUND AND OBJECTIVES: Systemic inflammation modulates cardiovascular disease risk and functionality of HDL in the setting of CKD. Whether interventions that modify systemic inflammation can improve HDL function in CKD is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a post hoc analysis of two randomized, clinical trials, IL-1 trap in participants with GFR 15-59 ml/min per 1.73 m2 (study A) and IL-1 receptor antagonist in participants on maintenance hemodialysis (study B), to evaluate if IL-1 blockade had improved the anti-inflammatory activity (IL-6, TNF-α, and Nod-like receptor protein 3), antioxidant function (superoxide production), and net cholesterol efflux capacity of HDL. HDL function was measured using LPS-stimulated THP-1 macrophages or peritoneal macrophages of apoE-deficient mice exposed to the apoB-depleted, HDL-containing fraction obtained from the plasma of the study participants, collected before and after the interventions to block IL-1 effects. Analysis of covariance was used for between group comparisons. RESULTS:The mean age of the participants was 60±13 years, 72% (n=33) were men, and 39% (n=18) were black. There were 32 CKD (16 IL-1 trap and 16 placebo) and 14 maintenance hemodialysis (7 IL-1 receptor antagonist and 7 placebo) participants. Compared with placebo, IL-1 inhibition, in study A and B reduced cellular expression of TNF-α by 15% (P=0.05) and 64% (P=0.02), IL-6 by 38% (P=0.004) and 56% (P=0.08), and Nod-like receptor protein 3 by 16% (P=0.01) and 25% (P=0.02), respectively. The intervention blunted superoxide production in the treated arm compared with placebo, with the values being higher by 17% in the placebo arm in study A (P<0.001) and 12% in the placebo arm in study B (P=0.004). Net cholesterol efflux capacity was not affected by either intervention. CONCLUSIONS:IL-1 blockade improves the anti-inflammatory and antioxidative properties of the HDL-containing fraction of plasma in patients with stages 3-5 CKD, including those on maintenance hemodialysis.
RCT Entities:
BACKGROUND AND OBJECTIVES: Systemic inflammation modulates cardiovascular disease risk and functionality of HDL in the setting of CKD. Whether interventions that modify systemic inflammation can improve HDL function in CKD is unknown. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We conducted a post hoc analysis of two randomized, clinical trials, IL-1 trap in participants with GFR 15-59 ml/min per 1.73 m2 (study A) and IL-1 receptor antagonist in participants on maintenance hemodialysis (study B), to evaluate if IL-1 blockade had improved the anti-inflammatory activity (IL-6, TNF-α, and Nod-like receptor protein 3), antioxidant function (superoxide production), and net cholesterol efflux capacity of HDL. HDL function was measured using LPS-stimulated THP-1 macrophages or peritoneal macrophages of apoE-deficientmice exposed to the apoB-depleted, HDL-containing fraction obtained from the plasma of the study participants, collected before and after the interventions to block IL-1 effects. Analysis of covariance was used for between group comparisons. RESULTS: The mean age of the participants was 60±13 years, 72% (n=33) were men, and 39% (n=18) were black. There were 32 CKD (16 IL-1 trap and 16 placebo) and 14 maintenance hemodialysis (7 IL-1 receptor antagonist and 7 placebo) participants. Compared with placebo, IL-1 inhibition, in study A and B reduced cellular expression of TNF-α by 15% (P=0.05) and 64% (P=0.02), IL-6 by 38% (P=0.004) and 56% (P=0.08), and Nod-like receptor protein 3 by 16% (P=0.01) and 25% (P=0.02), respectively. The intervention blunted superoxide production in the treated arm compared with placebo, with the values being higher by 17% in the placebo arm in study A (P<0.001) and 12% in the placebo arm in study B (P=0.004). Net cholesterol efflux capacity was not affected by either intervention. CONCLUSIONS:IL-1 blockade improves the anti-inflammatory and antioxidative properties of the HDL-containing fraction of plasma in patients with stages 3-5 CKD, including those on maintenance hemodialysis.
Authors: Seth G Thacker; Abdalrahman Zarzour; Ye Chen; Mustafa S Alcicek; Lita A Freeman; Dennis O Sviridov; Stephen J Demosky; Alan T Remaley Journal: Immunology Date: 2016-08-28 Impact factor: 7.397
Authors: Kristen L Nowak; Michel Chonchol; Talat Alp Ikizler; Heather Farmer-Bailey; Natjalie Salas; Rafia Chaudhry; Wei Wang; Gerard Smits; Isak Tengesdal; Charles A Dinarello; Adriana M Hung Journal: J Am Soc Nephrol Date: 2016-09-19 Impact factor: 10.121
Authors: Sandhya Sankaranarayanan; Margarita de la Llera-Moya; Denise Drazul-Schrader; Bela F Asztalos; Ginny L Weibel; George H Rothblat Journal: J Lipid Res Date: 2010-08-16 Impact factor: 5.922
Authors: Katherine P Liao; Martin P Playford; Michelle Frits; Jonathan S Coblyn; Christine Iannaccone; Michael E Weinblatt; Nancy S Shadick; Nehal N Mehta Journal: J Am Heart Assoc Date: 2015-01-30 Impact factor: 5.501
Authors: Jiansheng Huang; Patricia G Yancey; Huan Tao; Mark S Borja; Loren E Smith; Valentina Kon; Sean S Davies; MacRae F Linton Journal: Nutrients Date: 2020-06-30 Impact factor: 5.717
Authors: Wai W Cheung; Ronghao Zheng; Sheng Hao; Zhen Wang; Alex Gonzalez; Ping Zhou; Hal M Hoffman; Robert H Mak Journal: Sci Rep Date: 2021-07-23 Impact factor: 4.379